Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily injection administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight and side effects).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin Detemir; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 1 diabetes for more than 1 year

• Subject treated by any kind of insulin regimen and whatever the number of injections

• HbA1c = 7.5% and = 10%

Exclusion Criteria:

• Type 2 diabetes

• Treatment by oral anti-diabetic drugs

• Severe medical conditions